进展型多发性硬化与更快且特异性的视网膜层萎缩相关
该研究对178例复发缓解型多发性硬化(RRMS)、186例进展型多发性硬化(PMS)和66名对照进行中位3.7年的序列OCT随访。结果显示,PMS患者视网膜神经纤维层和神经节细胞+内丛状层的萎缩速度独立于年龄而快于RRMS,且内颗粒层和外核层的萎缩也快于RRMS和对照,而RRMS与对照无差异。PMS中疾病修饰治疗未影响视网膜萎缩速率。
要点
- PMS患者视网膜萎缩速度独立于年龄,快于RRMS。
- INL和ONL萎缩在PMS中更快,可能成为神经退行性变的生物标志物。
- PMS中疾病修饰治疗未影响视网膜层萎缩速率。
核心结论
- PMS与独立于年龄的更快视网膜萎缩相关。
- INL和ONL萎缩可能成为PMS神经退行性变的新型生物标志物,且不受常规疾病修饰治疗影响。
- 在纳入OCT结局的临床试验中应考虑年龄对萎缩速率的影响。
研究设计与样本
- 研究纳入178例RRMS、186例PMS和66名对照,进行序列OCT随访,中位随访3.7年。
主要发现
- MS中pRNFL和GCIPL萎缩归因于正常老化的比例从25岁时的42.7%和16.7%升至65岁时的83.7%和81.1%。
- 独立于年龄,PMS相比RRMS的pRNFL(-0.34 ± 0.09%/年,p < 0.001)和GCIPL(-0.27 ± 0.07%/年,p < 0.001)变薄更快。
- 基线年龄越高,INL和ONL变薄越快(MS和对照均如此)。
- PMS相比对照(INL:-0.09 ± 0.04%/年,p = 0.03;ONL:-0.12 ± 0.06%/年,p = 0.04)和RRMS(INL:-0.10 ± 0.04%/年,p = 0.01;ONL:-0.13 ± 0.05%/年,p = 0.01),INL和ONL变薄更快,而RRMS与对照相似。
- 与RRMS不同,疾病修饰治疗未影响PMS中视网膜层萎缩速率。
临床怎么用
- OCT衍生的视网膜层测量可用于监测PMS神经退行性变。
- INL和ONL测量可能是PMS中不受疾病修饰治疗影响的生物标志物。
- 临床试验纳入OCT结局时应考虑年龄对萎缩速率的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Therapeutic development in progressive multiple sclerosis (PMS) has been hampered by a lack of reliable biomarkers to monitor neurodegeneration. Optical coherence tomography (OCT)-derived retinal measures have been proposed as promising biomarkers to fulfill this role. However, it is unclear whether retinal atrophy persists in PMS, exceeds normal aging, or can be distinguished from relapsing-remitting multiple sclerosis (RRMS). METHODS: 178 RRMS, 186 PMS, and 66 control participants were followed with serial OCT for a median follow-up of 3.7 years. RESULTS: The estimated proportion of peripapillary retinal nerve fiber layer (pRNFL) and macular ganglion cell + inner plexiform layer (GCIPL) thinning in multiple sclerosis (MS) attributable to normal aging increased from 42.7% and 16.7% respectively at age 25 years, to 83.7% and 81.1% at age 65 years. However, independent of age, PMS was associated with faster pRNFL (-0.34 ± 0.09%/yr, p < 0.001) and GCIPL (-0.27 ± 0.07%/yr, p < 0.001) thinning, as compared to RRMS. In both MS and controls, higher baseline age was associated with faster inner nuclear layer (INL) and outer nuclear layer (ONL) thinning. INL and ONL thinning were independently faster in PMS, as compared to controls (INL:-0.09 ± 0.04%/yr, p = 0.03; ONL:-0.12 ± 0.06%/yr, p = 0.04), and RRMS (INL:-0.10 ± 0.04%/yr, p = 0.01; ONL:-0.13 ± 0.05%/yr, p = 0.01), whereas they were similar in RRMS and controls. Unlike RRMS, disease-modifying therapies (DMTs) did not impact rates of retinal layer atrophy in PMS. INTERPRETATION: PMS is associated with faster retinal atrophy independent of age. INL and ONL measures may be novel biomarkers of neurodegeneration in PMS that appear to be unaffected by conventional DMTs. The effects of aging on rates of retinal layer atrophy should be considered in clinical trials incorporating OCT outcomes. ANN NEUROL 2020;87:885-896.
引用
- Sotirchos ES, Gonzalez Caldito N, Filippatou A, et al. Progressive Multiple Sclerosis Is Associated with Faster and Specific Retinal Layer Atrophy. Ann Neurol. 2020. PMID: 32285484. doi:10.1002/ana.25738
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。